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The helminth parasite Fasciola hepatica 
secretes cysteine proteases to facilitate tissue-
invasion, migration and development within 
the mammalian host. The major proteases 
cathepsin L1 (FheCL1) and cathepsin L2 
(FheCL2) were recombinantly produced and 
biochemically characterised. Using site-
directed mutagenesis we show that residues at 
position 67 and 205, which lie within the S2 
pocket of the active site, are critical in 
determining the substrate and inhibitor 
specificity. FheCL1 exhibits a broader 
specificity and a higher substrate turnover 
rate compared to FheCL2. However, FheCL2 
can efficiently cleave substrates with a Pro in 
the P2 position and degrade collagen within 
the triple helices at physiological pH, an 
activity that among cysteine proteases has 
only been reported for human cathepsin K.  
The 1.4 Å three-dimensional structure of the 
FheCL1 has was determined by X-ray 
crystallography and the three-dimensional 
structure of FheCL2 constructed via 
homology-based modelling. Analysis and 
comparison of these structures and our 
biochemical data with those of human 
cathepsins L and K provided an 
interpretation of the substrate-recognition 
mechanisms of these major parasite 
proteases. Furthermore, our studies suggest 
that a configuration involving residue 67 and 
the ‘gatekeeper’ residues 157 and 158 situated 
at the entrance of the active site pocket create 
a topology that endows FheCL2 with its 
unusual collagenolytic activity. The 
emergence of a specialised collagenolytic 
function in Fasciola likely contributes to the 
success of this tissue-invasive parasite. 
 
Clan CA papain-like cysteine peptidases, 
such as cathepsins B and L, (1; 
www.merops.sanger.ac.uk) are ubiquitous in 
helminth (worm) parasites of human and 
veterinary importance.  These peptidases are 
involved in a variety of pathogen-specific 
functions including penetration and migration 
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through host tissues, catabolism of host proteins 
to peptides and amino acids, and modulation or 
suppression of host immune defences by 
cleaving immunoglobulin or altering the activity 
of immune effector cells (2, 3, 4). The central 
role of Clan CA proteases in the survival of 
helminth parasites has positioned them as lead 
targets for the development of new 
chemotherapies and vaccines (5, 6, 7). 
Fasciola hepatica is a helminth parasite 
that causes liver fluke disease (fasciolosis) in 
cattle and sheep world-wide. It is most prevalent 
in Europe with infection rates increasing due to 
the emergence of drug-resistant parasites, and 
possibly as a result of climate change (8, 9). 
Human fasciolosis has recently emerged as a 
major zoonosis in rural areas of South America, 
(particularly Bolivia, Peru and Equador), Egypt 
and Iran where organised farm management 
practices are poor. It is estimated that worldwide 
over 2.4 million people are infected with F. 
hepatica and about 180 million are at risk of 
infection (10, 11). 
Secretion of cysteine proteases is 
associated with the virulence of F. hepatica, and 
its capacity to infect a wide range of mammalian 
hosts (4, 6, 12, 13, 14). Cathepsin L1 (FheCL1) 
and cathepsin L2 (FheCL2) are the two major 
peptidases secreted by the infective larvae that 
traverse the host intestinal wall, by the migratory 
stages that penetrate the liver tissues and by the 
mature adult parasites that reside in the bile 
ducts and feed on host blood, which they ingest 
through the punctured bile duct wall (4, 6, 15). 
Experiments using purified native enzymes 
demonstrated that FheCL1 and FheCL2 
efficiently degrade host haemoglobin, 
immunoglobulin and interstitial matrix proteins 
such as fibronectin, laminin and native collagen 
(6, 16, 17). While FheCL1 and FheCL2 
exhibited similar substrate specificities FheCL2 
showed a greater affinity for peptides containing 
Pro residues in the P2 position (18, 19, 20). We 
proposed that by producing proteases with 
overlapping specificity the parasite could digest 
these host macromolecules more efficiently, and 
therefore more effectively penetrate host organs 
(6, 16).  
The F. hepatica cathepsin Ls belong to a 
lineage that eventually gave rise to the 
mammalian cathepsin Ls from which the 
mammalian cathepsin Ks diverged (2). 
Mammalian cathepsin L is ubiquitously 
expressed in tissues and performs a house-
keeping function in protein turnover, but also 
plays a part in more specialised functions such as 
antigen processing and presentation, hormone 
and protease activation and extra-cellular matrix 
turnover (21).  Cathepsin K, on the other hand, 
exhibits a more restricted expression profile 
being predominantly found in osteoclasts, but 
also in multinucleated giant cells, macrophages 
and lung epithelial cells (22, 23).  A specific role 
for cathepsin K in bone resorption by osteoclasts 
has been related to the protease’s ability to 
cleave the covalently-linked triple helices of 
native collagen, a unique property amongst the 
mammalian papain-like cysteine proteases (24). 
This unusual property was attributed to the 
presence of a tyrosine residue at position 67 
within the S2 subsite of cathepsin K that 
interacts with proline in the P2 of substrates, 
including the Gly-Pro-Xaa repeat sequence 
(where Xaa is mainly proline or 4-trans-L-
hydroxyproline) found in collagen. A parallel, 
therefore, exists between mammalian cathepsin 
K and the F. hepatica FheCL2 as the latter can 
also cleave substrates with a P2 proline and 
possesses a tyrosine residue at the corresponding 
position 67. 
 To understand the role of the major 
secreted cathepsin L proteases of F. hepatica in 
the virulence of the parasite and its adaptation to 
various hosts, it is important to elucidate their 
biochemical properties and relate these to 
structure and function. In the present study, 
therefore, we have characterised the substrate 
specificity of active recombinant forms of 
FheCL1 and FheCL2. These properties were 
further explored by preparing variants of 
FheCL1 in which specific substitutions were 
made within the S2 subsite of the active site 
(positions 67 and 205) in order to simulate those 
residues present in human cathepsins L and K. In 
addition, the 1.4 Å three-dimensional structure 
of a variant FheCL1 zymogen, in which the 
active site Cys was replaced by a Gly 
(FheproCL1Gly25), has been determined by X-
ray crystallography.  For FheCL2, the three-
dimensional structure has been constructed via 
homology-based modelling. Analysis and 
comparison of these major parasite proteases 










with the human cathepsins L and K provide a 










NHMec and Z-Phe-Ala-CHN2 were obtained 
from Bachem (St. Helens, UK).  Z-Leu-Arg-
NHMec was purchased from Peptide Institute 
Inc. (Japan).  E-64, DTT and EDTA were 
obtained from Sigma-Aldrich (Sydney, 
Australia). Cathepsin K Inhibitor II was 
purchased from Biosciences (CA, USA). 
Prestained molecular weight markers and the 
AvrII and SnaBI restriction enzymes were 
obtained from New England Biolabs (UK) Ltd. 
(Hitchin, UK).  Primers were obtained from 
Sigma-Genosys (Pampisford, UK).  The pPIC9K 
vector and Pichia pastoris strain GS115 were 
obtained from Invitrogen Corp. (San Diego, CA, 
USA).  Ni-NTA agarose and columns were 
obtained from Qiagen (Crawley, UK). Collagen, 
calf skin, was purchased from Calbiochem (San 
Diego, CA). Pre-cast 4-20% gradient SDS-
PAGE gels were purchased from Gradipore 
(Australia). 
 
Expression and purification of recombinant 
cathepsin L  zymogens in yeast 
F. hepatica procathepsin L1 (FheCL1) and 
procathepsin L2 (FheCL2) were amplified by 
PCR from the pAAH5 Saccharomyces cerevisiae 
expression vector into which the full-length 
cDNA had been previously cloned in our 
laboratory (12, 25). FheCL1 variants (FheCL1 
Leu67Tyr and FheCL1 Leu205Ala) were 
synthesized and incorporated a SnaBI restriction 
site at the 5’ end of the gene and an AvrII 
restriction site and His6-tag sequence at the 3’ 
end (Geneart, Regensburg, Germany). The 
980bp fragments were ligated into pCR-Script 
cloning vector (Stratagene, CA, USA) which 
were transformed into competent E. coli for 
amplification. Inserts were digested from 
plasmid preparations with AvrII and SnaB1 and 
inserted in-frame with the yeast alpha-factor at 
the AvrII/SnaB1 site of Pichia pastoris 
expression vector pPIC9K (Invitrogen). Plasmids 
were linearized with SacI and then transformed 
into chemically competent GS115 cells 
(Invitrogen) as described previously (12). All 
inserts were sequenced to ensure congruence 
with original cDNAs.  
Pichia pastoris yeast transformants were 
cultured in 500 ml BMGY broth, buffered to pH 
8.0, in 5 L baffled flasks at 30°C until an OD600 
of 2-6 was reached (12).  Cells were harvested 
by centrifugation at 2000 x g for 5 min and 
protein expression induced by resuspending in 
100 ml BMMY broth, buffered at pH 6.0 
containing 1% methanol (Dowd et al, 1997). 
Recombinant proteins were purified from yeast 
medium by affinity chromatography using Ni-
NTA-agarose (Qiagen) (12, 26). Purified 
recombinant zymogens were dialysed against 
phosphate buffered saline (PBS) and stored at –
20oC. The 37 kDa zymogens were auto-
catalytically activated and processed to 24.5 kDa 
mature enzymes by incubation for 2 hours at 
37ºC in 0.1 M sodium citrate buffer pH 5.0, 
containing 2 mM DTT and 2.5 mM EDTA. The 
mixture was then dialysed against PBS, pH 7.3. 
The proportion of functionally active 
recombinant protein in these preparations was 
determined by titration against E-64. 
 
 
P1-P4 specificity using a positional-scanning 
synthetic combinatorial library 
The substrate specificities of FheCL1, FheCL1 
Leu67Tyr and FheCL1 Leu205Ala and FheCL2 
were determined using a complete diverse 
positional-scanning synthetic combinatorial 
library (PS-SCL; 27).  Screens were performed 
at 25ºC in 0.1 M sodium acetate, 0.1 M NaCl, 
0.01 M DTT, 0.001 M EDTA, 0.01% Brij-35, 
1% DMSO (from the substrates), pH 5.5. 
Aliquots of 25 nmol in 1 µl from each of 20 sub-
libraries of the P1-, P2-, P3-, and P4-libraries 
were added to the wells of a 96-well Microfluor-
1 U-bottom plate (Dynex Technologies). The 
final concentration of each compound of the 
8000 compounds per well was 31.25 nM in a 
100 µl final reaction volume. The assays were 
initiated by addition of preactivated enzyme and 
the reaction was monitored with a SpectraMax 
Gemini fluorescence spectrometer (Molecular 










Devices) with excitation at 380 nm, emission at 
460 nm, and cut-off at 435 nm.  Screens were 
performed in duplicate and triplicate for 
wildtype and mutated enzymes, respectively.    
 
Enzyme assays and kinetics with fluorogenic 
peptide substrates 
Initial rates of hydrolysis of the fluorogenic 
dipeptide substrates were measured by 
monitoring the release of the fluorogenic leaving 
group, NHMec, at an excitation wavelength of 
380 nm and an emission wavelength of 460 nm 
using a Bio-Tek KC4 microfluorometer.  kcat and 
KM values were determined using nonlinear 
regression analysis.  Initial rates were obtained at 
37°C over a range of substrate concentrations 
spanning KM (0.2 – 200 µM) and at fixed 
enzyme concentrations (0.5 – 5 nM).  Assays 
were performed in PBS, pH 7.3, and 100 mM 
sodium acetate buffer, pH 5.5, each containing 
2.5 mM DTT and 2.5 mM EDTA. 
Rate constants for the inactivation of 
enzyme by Z-Phe-Ala-CHN2 and Cathepsin K 
Inhibitor II were determined from progress 
curves in the presence of substrate (28, 29).  
When substrate and inhibitor bind to enzyme in 
rapid equilibrium and the substrate concentration 
does not change significantly during the course 
of the assay, the concentration of product, [P], at 
time t after the start of the reaction is given by 
the equation 







where v0 is the initial rate of reaction, kobs is the 
rate of inactivation and A0 is the background 
fluorescence.  kobs is related to the inhibitor 
concentration by the equation 
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  (2) 
When [I]<<Ki plots of kobs versus [I] were linear 
with slope equal to an apparent second-order rate 
constant kobs/[I].  This value was then corrected 
for substrate concentration and the Michaelis 
constant to determine a true second-order rate 
constant kinact/Ki. 
The initial rate v0 is related to inhibitor 
concentration by the equation 
[ ]




















  (3) 
Since the inactivation was carried out with 











=   (4) 
An apparent inhibition constant Ki(app) for the 
formation of the initial reversible enzyme-
inhibitor complex prior to inactivation was 
determined by plotting v0 against [I] and fitting 
to equation (4). 
 
Collagen digestion 
Calf skin collagen type-1 was solublized in 0.2 
M acetic acid at a concentration of 2 mg/ml and 
dialysed for two days against 0.1 M sodium 
acetate, pH 4.0, 0.1 M sodium acetate, pH 5.5, or 
PBS, pH 7.3. Reactions contained 10 µg of 
dialyzed collagen type-1, 1 mM DTT and 2 mM 
EDTA and 5.47 µM activated peptidase in a final 
volume of 100 µl of one of the above buffers. 
Reactions were performed at 28 °C for 3 and 20 
h, or at 37°C for 30 min. All reactions were 
stopped by the addition of 10 µM E-64. Collagen 
digests were analyzed by 4-20% gradient SDS-
PAGE under reducing conditions and stained 
with Coomassie Brilliant Blue R-250. 
 
Production of inactive variant FheproCL1 Gly25  
For the purpose of obtaining a high-resolution 
three-dimensional structure of FheCL1, an 
inactive enzyme was produced by replacing the 
active site Cys residue at position 25 in the 
mature domain by a Gly (12, 26). This 
FheproCL1 Gly25 enzyme migrated as a single 
protein of 37 kDa on reducing 12% SDS-PAGE 
which represents the full zymogen containing a 
prosegment and mature enzyme domain (data 
not shown).  
 
Data collection, structure solution and 
crystallographic refinement of FheproCL1 Gly25   
Initial crystallization screening experiments were 
performed at the Hauptman-Woodward Institute 
high-throughput crystallization lab. A total of 
1536 conditions were tested using a nano-scale 










microbatch-under-oil method, resulting in 
several preliminary hits that suggested a route to 
diffraction-quality crystals (30). Ultimately, 
high-quality crystals were grown in house via 
vapor diffusion in sitting drops. One µL of 10 
mg/ml FheproCL1 Gly25 enzyme was mixed with 
one µL of the precipitating agent, 0.2 M NaSCN 
in 20% PEG 3350, and allowed to equilibrate at 
23°C over a 100 µL reservoir of precipitating 
agent. Crystalline plates formed within two days, 
however, full-size growth to plates greater than 
75 µm in thickness took nearly two months time.  
Diffraction data were collected at the 
Advanced Light Source (ALS), beam line 8.3.1, 
using monochromatic (Si 111) radiation of 
1.11588 Å (31). An ADSC Quantum 210 2x2 
CCD array detector was used with low-
temperature conditions of 100 K at the crystal 
position. Crystals of the single mutant protein 
were flash-cooled in liquid nitrogen after being 
soaked for approximately 1.5 minutes in a cryo-
protectant solution of crystal-growth solution 
plus 50% MPD.  High- and low-resolution 
datasets were collected from the same crystal. 
Data processing was completed with MOSFLM 
(32) and SCALA. The structure was solved via 
molecular replacement using the MOLREP 
program of the CCP4 suite (33) with a 
polyserine search model derived from the 1.8 Å 
structure of 1CS8 (human procathepsin L). The 
topmost solution had an R-factor value of 0.535 
and correlation coefficient of 0.288, each several 
sigma levels above the next best solution, which 
had corresponding statistics of 0.604 and 0.083, 
respectively. One unique solution was found 
with one molecule in the asymmetric unit and a 
starting Rfactor of 0.526. The initial molecular 
replacement solution was improved using 
ARP/wARP as implemented in the CCP4 
program suite (34) resulting in a model that was 
better than 85% complete. Iterative rounds of 
visualization and manual model building and 
refinement were completed with QUANTA 
(Accelrys, San Diego, CA) and Refmac5 with 
anisotropic atomic displacement parameters (35), 
respectively. Water molecules were added 
automatically using ARPwaters in CCP4 (36) 
and were manually verified. In the final stages of 
refinement, XPLEO (37) was used to improve 
the fit of two areas of ambiguous density in the 
structure. Final visualization and manual 
adjustments to the structure as well as final 
assessment of water molecules were completed 
with COOT (38). Crystallographic parameters 
and statistics are summarized in Table 1 and 
final atomic coordinates have been deposited 
with the Protein Data Bank, accession ID 2O6X. 
 
Homology-based molecular modelling 
A model structure of the mature domain of 
FheCL2 was built using Modeller (release 8v1), 
a program for protein structure modelling (39, 
40, 41). The 1.8 Å structure of human 
procathepsin L (PDB ID 1CS8), the 2.2 Å 
structure of human cathepsin K (PDB ID 1ATK) 
and our 1.4 Å solved structure of FheproCL1 
Gly25 were used as three-dimensional templates 
of related fold. Generated models were 
visualized and compared with COOT (37) and 
with PyMOL (42). 
 
Sequence analysis 
F. hepatica cathepsin L protein 
sequences were aligned using ClustalX 1.81.  
Phylogenetic trees were generated from the 
alignment by the boot-strapped (1000-trial) 




Active site residues involved in substrate 
specificity of FheCL1 and FheCL2 
Residues that make up the S2 pocket of FheCL1 
and FheCL2 were determined using the three-
dimensional X-ray crystal structure of FheCL1 
and homology-based model of FheCL2, 
respectively, (see below) and their comparison to 
the structure of human cathepsin L (PDB ID: 
1CS8) and cathepsin K (PDB ID: 1ATK) are 
shown in Table 2 (see also Fig. 1 and 7A; papain 
numbering is used). Most variation between 
papain cysteine proteases occurs at residues 67 
and 205, and studies with human cathepsin L and 
cathepsin K demonstrated that the difference in 
residues 67 (Leu and Tyr, respectively) and 205 
(Ala and Leu, respectively) reflect the striking 
difference in the substrate specificity of these 
two enzymes; for example, human cathepsin L 
exhibits a broad specificity and favours both 
aromatic and aliphatic P2 residues but will not 
accept proline, whereas cathepsin  K prefers only 










aliphatic resides and most particularly proline. 
Indeed, the acceptance of a P2 Pro residue 
confers cathepsin K with it unique ability to 
cleave native type I and type II collagens, 
proteins that contain repeated Gly-Pro-X motifs 
(44). Like human cathepsin L, FheCL1 possesses 
a Leu at position 67; however, unlike cathepsin 
L it possesses a Leu at position 205 rather than 
an Ala. The Leu at position 205 is similar to 
cathepsin K and, thus, the FheCL1 exhibits 
hybrid character in the S2 subsite. By contrast, 
FheCL2 possesses a Tyr at position 67 and Leu 
at position 205 and, hence, is identical to 
cathepsin K at both sites. It has been suggested 
by us (2) and others (44, 45) that the 
accommodation of Pro in the P2 position of 
peptide substrates by FheCL2 may be related to 
the presence of the Tyr67, analogous to the 
cathepsin K scenario. 
To address the relationship between the 
residues presented at position 67 and 205 and the 
substrate specificity and function of FheCL1 and 
FheCL2, we prepared variants of FheCL1 as 
shown in Table 2. The FheCL1 Leu67Tyr 
variant has a single amino acid change making 
the S2 subsite similar to FheCL2 and cathepsin 
K at positions 67 and 205. The FheCL1 
Leu205Ala variant has a single amino acid that 
was designed to make the S2 subsite similar to 
human cathepsin L. The wildtype and variant F.  
hepatica cathepsin L peptidases were 
recombinantly-expressed in the methylotrophic 
yeast Pichia pastoris, purified and activated as 
described in materials and methods. All enzymes 
were expressed as 37 kDa zymogens that 
autocatalytically processed at pH 4.5 to produce 
24.5 kDa mature enzymes, which was confirmed 
by N-terminal sequencing (Fig. 2). Enzymatic 
assays showed that all substitutions made in the 
S2 subsite of the FheCL1 active site did not alter 
its pH profile for activity against the fluorogenic 
substrate Z-Phe-Arg-NHMec; both the wildtype 
and variant free enzymes exhibited a Gaussian 
bell-shaped pH profile with an optimum for 
activity in the region pH 6.5 to 7.0 (pKI = 3.87 ± 
0.07 and pKII 8.14 ± 0.08).  
 
Substrate specificity profiling using a PS-SCL 
reveals unique and distinct activities of FheCL1 
and FheCL2. 
Wildtype FheCL1 and FheCL2 exhibited similar 
preferences for amino acids at P1. As expected 
for papain-like cysteine proteases, both enzymes 
had a clear preference for Arg at P1 but other 
residues accommodated in this position included 
Lys, Glu, Thr and Met (Fig. 3, P1 column), and 
these were all cleaved at similar relative rates to 
that observed for human cathepsin L and 
cathepsin K (44). Similar results were obtained 
for the variants FheCL1 Leu67Tyr and FheCL1 
Leu205Ala, which were expected as the 
introduced substitutions do not affect the S1 
active site pocket (not shown).  
 A P1-Arg fixed library was then used to 
explore P2-P4 specificities of FheCL1 and 
FheCL2. The enzymes show a distinct 
preference for hydrophobic amino acids in the 
P2; both favoured Leu. Interestingly, however, 
the positional scanning method did not identify 
Phe as a suitable P2 residue even though our 
kinetic studies demonstrate that both FheCL1 
and FheCL2, like other papain cysteine 
proteases, cleave fluorogenic substrates with a 
P2 Phe efficiently (see Table 3). The most 
striking observation was the distinct preference 
for Pro residues by FheCL2, particularly when 
compared to FheCL1 that did not accommodate 
this residue (Fig. 3, P2 column). The unusual 
preference for a P2 Pro exhibited by FheCL2 is 
similar to that observed for human cathepsin K 
using the same methodology (44). However, 
whereas human cathepsin K favoured equally Ile 
and Leu at P2 (44), both Fasciola cathepsins 
were more similar to human cathepsin L by 
preferring Leu over Ile.  
 The replacement of Leu for Ala at 
residue 205 (FheCL1 Leu205Ala) markedly 
altered the activity profile from wildtype enzyme 
(Fig. 4). This variant exhibited a broader 
substrate specificity by accepting Phe, Trp and 
Tyr at P2, residues that were not accepted by 
wildtype FheCL1. The same residues are also 
accommodated by human cathepsin L (44), thus 
demonstrating that the replacement of Leu205 
for Ala in FheCL1 generates an enzyme more 
similar to the human orthologue. By contrast, the 
FheCL1 Leu67Tyr variant did not show a 
significant change in the P2 preference to 
wildtype FheCL1; in particular, this substitution 
did not alter the activity of the enzyme towards 
Pro in the P2 position (Fig. 4). This was a 










surprising result as we expected that the FheCL1 
Leu67Tyr variant would behave similarly to 
FheCL2 and cathepsin K given that the residues 
at positions 67 and 205 were identical. 
As anticipated, the P3 and P4 
specificities for FheCL1 and FheCL2 were 
similar, and like human cathepsin L and 
cathepsin K, the Fasciola enzymes accepted a 
broad range of residues in these positions. The 
P3-P4 specificity of FheCL1 was unaffected by 
the P2 substitutions present in the variant 
proteases (not shown). 
 
Wildtype and variant protease specificities 
against fluorogenic peptide substrates correlates 
with residues at position 67 and 205  
To support and extend the data derived from the 
positional scanning libraries, and to determine 
substrate kinetic parameters (KM, kcat and kcat 
/KM) for wildtype FheCL1, the variants FheCL1 
Leu67Tyr, and FheCL1 Leu205Ala and wildtype 
FheCL2, we examined their hydrolytic activity 
against various fluorogenic di- and tri-peptides 
(Table 3). FheCL1 efficiently cleaved both Z-
Phe-Arg-NHMec (kcat /KM = 1,021,092 M-1s-1) 
and Z-Leu-Arg-NHMec (kcat /KM = 8,395,402 M-
1s-1); the enzyme cleaved the latter substrate over 
eight times more rapidly largely because its KM 
for this substrate is much lower than for the 
former substrate. Although the substrates Z-Pro-
Arg-NHMec (kcat /KM = 5,387 M-1s-1), Tos-Gly-
Pro-Arg-NHMec (kcat /KM = 35,928 M-1s-1) and 
Boc-Ala-Gly-Pro-Arg-NHMec (kcat /KM =  
46,021 M-1s-1) were cleaved relatively poorly the 
data, nevertheless, indicates that FheCL1 can 
accommodate proline residues in the P2 position.  
In comparison to FheCL1, FheCL2 is 
much less efficient at cleaving substrates with 
Phe and Leu in the P2 position; the kcat/KM 
values for Z-Phe-Arg-NHMec and Z-Leu-Arg-
NHMec with this enzyme are 24-fold and 7-fold 
lower than for FheCL1, respectively.  However, 
its ability to cleave Z-Pro-Arg-NHMec, Tos-
Gly-Pro-Arg-NHMec and Boc-Ala-Gly-Pro-
Arg-NHMec is 6-, 2- and 2-fold higher than that 
of FheCL1 (Table 3).  This kinetic data shows 
that the S2 subsite of FheCL2 is able to 
accommodate proline residues more readily than 
the S2 subsite of FheCL1, and is in agreement 
with the data obtained by PS-SCL (Figs. 3 and 
4). 
 Substitution at the 205 position of 
FheCL1 to generate variant FheCL1 Leu205Ala 
had a significant impact on the enzyme’s 
substrate specificity by increasing its ability to 
cleave Z-Phe-Arg-NHMec, while reducing its 
effectiveness on Z-Leu-Arg-NHMec, Z-Pro-Arg-
NHMec, Tos-Gly-Pro-ArgNHMec and Boc-Ala-
Gly-Pro-Arg-NHMec (Table 3). Substitution at 
position 67 to give the variant FheCL1 Leu67Tyr 
reduced the efficiency of the enzyme for both Z-
Phe-Arg-NHMec and Z-Leu-Arg-NHMec about 
2-fold, which was reflected in a reduction of 
both kcat and KM values for each substrate. This 
substitution did not significantly alter the 
enzyme’s specificity for the substrate Z-Pro-Arg-
NHMec, or Tos-Gly-Pro-Arg-NHMec, although 
it almost doubled its efficiency on Boc-Ala-Gly-
Pro-Arg-NHMec (Table 3).  
 
Kinetic analyses of wildtype and variant 
proteases with specific inhibitors 
Peptidyl diazomethylketones are irreversible 
inhibitors of cysteine proteases (46). Changes in 
rates of inactivation by these inhibitors have 
highlighted different specificities at subsites of 
cysteine proteases such as cathepsin L and 
cathepsin B (47). In this study, rates of 
inactivation of FheCL1, FheCL1 Leu205Ala, 
FheCL1 Leu67Tyr and FheCL2 by the cathepsin 
inhibitor Z-Phe-Ala-CHN2 have been measured. 
Wildtype FheCL1 and FheCL2 had second-order 
rate constants of 20,838 M-1s-1 and 11,899 M-1s-1, 
respectively, showing that both enzymes were 
rapidly inactivated by Z-Phe-Ala-CHN2 (Table 
4). The two-fold greater rate of inactivation of 
FheCL1 compared to FheCL2 is further evidence 
that FheCL1 accommodates hydrophobic P2 
residues more effectively than FheCL2. 
 The rate of inactivation of FheCL1 
Leu205Ala was 24-fold greater than wildtype 
indicating that Ala at residue 205 in the S2 
subsites binds a P2 Phe more effectively that a 
Leu which is consistent with our substrate 
kinetics studies (Table 3) and data derived from 
our tetrameric peptide library.  These data 
highlighted further the major impact that Ala at 
position 205 has on binding P2 residues, and it is 
interesting to note that the second-order rate 
constant of 492,727 M-1s-1 (Table 4) for the 
inactivation of FheCL1 Leu205Ala by Z-Phe-
Ala-CHN2 is similar to the value of 660,000 M-










1s-1 for the inactivation of mammalian cathepsin 
L by the same inhibitor (47, 48). By contrast, the 
FheCL1 Leu67Tyr variant had a kobs/[I] value of 
53,704 M-1s-1 (Table 4), which is only 2.5-fold 
higher than wildtype FheCL1 and 5-fold greater 
than wildtype FheCL2 and, therefore, this 
substitution has not such a major influence on 
the binding of Phe in the S2 pocket.  
 The inhibitor known as Cathepsin K 
Inhibitor II (Z-L-NHNHCONHNH-LF-Boc, 
CKII) is a potent time-dependent inhibitor of 
human cathepsin K; its selectivity for this 
enzyme is largely due to the effectiveness by 
which leucine occupies the S2 subsite (49). 
FheCL1 and FheCL2 were both potently 
inhibited by cathepsin K Inhibitor II with kobs/[I] 
values of 397,237 M-1s-1 and 269,447 M-1s-1, 
respectively, which are twenty times higher than 
that observed for the peptidyl diazomethylketone 
Z-Phe-Ala-CHN2 (compare Tables 4 and 5). 
These values are similar to the value of 590,000 
M-1s-1 reported for the inactivation of cathepsin 
K by Wang et al, (49). This data is consistent 
with the kinetic data for hydrolysis of peptidyl 
fluorogenic substrates as both enzymes had 
highest kcat/KM values for Z-Leu-Arg-NHMec. 
 The rate of inactivation of FheCL1 
Leu205Ala by cathepsin K Inhibitor II was 7-
fold lower than wildtype. The Ki(app) increased 
11-fold demonstrating that this variant cannot 
accommodate leucine in the S2 subsite to the 
same extent as wildtype FheCL1.  Since the rate 
of inactivation of human cathepsin L by 
cathepsin K Inhibitor II was 53-fold lower than 
that for human cathepsin K (Table 5), these data 
indicate that the FheCL1 Leu205Ala variant has 
S2 specificity more characteristic of human 
cathepsin L. The rate of inactivation of 
FheCL1Leu67Tyr by cathepsin K Inhibitor II 
was 3.5-fold lower than wildtype, although the 
Ki(app) did not change significantly, against 
showing that the Tyr substitution at this position 
exerts a relatively lower affect on P2 binding.  
 
Wildtype FheCL2 but not wildtype FheCL1 or its 
variants cleave native collagen type 1 
FheCL1 and FheCL2 degraded type 1 collagen at 
pH 4.0 and 5.5 in reactions held at 28oC but the 
activity of FheCL1 was much less and was 
limited to the β and γ chains while the α1 and α2 
chains remained intact. Moreover, whereas 
FheCL1 produced clear degradation fragments, 
FheCL2 degraded the collagen completely, 
particularly at pH 4.0, indicating that only the 
latter cleaves efficiently within the helical 
structures (Fig. 5, Panel A). Since low pH may 
cause some structural unravelling of the 
collagen, additional studies were performed at 
neutral pH. FheCL1 and FheCL2 both exhibit 
optimum activity against fluorogenic substrates 
in the neutral pH range. However, FheCL1 
exhibited minimal activity against type 1 
collagen in PBS, pH 7.3, whereas FheCL2 
cleaved within all collagen chains (Fig. 5, Panel 
B).  
Like the wildtype FheCL1 enzyme, 
FheCL1 Leu205Ala and FheCL1 Leu67Tyr 
variants cleaved collagen but were unable to 
cleave within the tightly wound helices. While in 
all experiments FheCL1 Leu205Ala appeared to 
cleave collagen more efficiently than the 
wildtype enzyme, the pattern of digested 
fragments was similar (Fig. 5, Panel B). 
Nevertheless, the greater efficiency of cleavage 
of collagen is consistent with this variant’s 
enhanced activity against fluorogenic substrates 
(Table 3). The inability of the FheCL1 Leu67Tyr 
variant to cleave within the helices of collagen is 
also consistent with the PS-PCL studies and 
substrate kinetics studies since this enzyme did 
not show any increase in preference for P2 Pro 
compared to wildtype FheCL1. 
 
The FheproCL1Gly25structure in comparison to 
other Clan CA cysteine proteases. 
The experimentally determined structure of 
FheproGL1Gly25 is quite similar to that of 
previously described mammalian cathepsins. 
While the X-ray crystal structure of FheCL1 
presented here is that of an inactive zymogen 
mutant in which active site Cys 25 has been 
mutated to glycine, the remainder of the active 
site machinery is intact and the key specificity 
determinant, the S2 pocket, has not been altered.   
 The molecule, FheproCL1Gly25, is 
similar in tertiary structure to human cathepsin 
L1. Electron density is clear, connected and 
easily traceable for the entirety of the mainchain 
of the mature domain of FheproCL1Gly25. The 
mature domain is bi-lobed, with a substrate 
binding cleft running between the two lobes of 
the enzyme, which is characteristic of the papain 










super-family of cysteine proteases (Fig. 6A). 
With the exception of the mutated catalytic 
cysteine at position 25, the expected catalytic 
machinery, highlighted in magenta in Fig. 6A, is 
present in the area of the substrate-binding cleft. 
The left-hand lobe of the mature domain (Fig. 
6A), is predominantly helical in composition. 
The second domain contains several elements of 
β-sheet. Similar to other members of the papain 
super-family of enzymes there are three disulfide 
bonds in the mature domain of FheCL1 Gly25. 
These connect Cys 22–Cys 63, Cys 56–Cys 95 
and Cys 153–Cys 200, respectively. 
Superimposition of the alpha carbons of the 
mature domain of FheproCL1 Gly25 on those of 
active papain (PDB entry ID: 9PAP) yields an 
r.m.s. deviation of 1.085 Å (the primary structure 
FheCL1 exhibits 32.8% identity and 62% 
similarity to papain). Superimposition of the 
main-chain atoms of the mature domain of 
FheproCL1 Gly25 on those of the mature domain 
of human cathepsin L yields an r.m.s. deviation 
of 0.780 Å, while superimposition of the two 
full-length molecules (PDB ID 1CJL) yields 
1.115 Å (the primary structure FheCL1 exhibits 
42.8% identity and 71% similarity to human 
cathepsin L). These structural comparisons are 
indicative of the high degree of overall fold and 
shape similarity that exists amongst the family of 
papain-like cysteine proteases (1, 
www.merops.sanger.ac.uk). 
The prosegment of FheproCL1 Gly25 
folds in a manner very similar to human 
cathepsin L – as indicated by the value given for 
superimposition above – though it does show 
more divergence than is observed in the mature 
domain. In general, there is a globular region and 
an extended C-terminal portion, as illustrated in 
Fig. 6B, that connects the prosegment to the 
mature domain.  As was described for human 
procathepsin L, the globular portion of the 
prosegment is fairly well structured and is 
comprised of distinct components of helix and 
beta-strand (50). One notable change in the 
structure as compared to the human zymogen 
structure is as follows. In FheproCL1Gly25, a 
stretch of beta strand extends from 79P through 
84P, which is then followed by a very short 
helical turn from 85P to 88P. In the human 
enzyme, this final helical turn is absent and this 
segment as well as the remainder of the 
prodomain is made up of beta strand only. The 
final visible residues of FheproCL1Gly25, 89P 
through 96P are beta strand. It should be noted 
that the two species show the greatest structural 
divergence from residues 85P to 96P, with the 
chains carving a somewhat different path 
through three-dimensional space. The final four 
residues (97P, 98P, 99P, 100P) of the 
prosegment of FheproCL1 Gly25 are not visible 
in experimental electron density, which suggests 
that they are disordered and subject to motion 
within the crystal. Most of the prosegment of 
FheproCL1 Gly25 sits adjacent to one side of the 
mature domain, in the region of a loop that 
extends from approximately residues 138 to 155 
of the mature domain. The corresponding area of 
contact in the prosegment is residues 55P 
through 68P.  The extended C-terminal tether of 
the prosegment that links the two domains lies 
across the active site cleft of the mature domain 
(Fig. 6B). 
 
Significant differences exist in the active site 
clefts of FheCL1 and FheCL2. 
The composition of the active site cleft, 
particularly the deep and well-defined S2 pocket 
is a key determinant of the substrate specificity 
of the papain family of cysteine proteases (44). 
The ability to accept or exclude particular 
substrate moieties is highly dependent upon the 
size, shape and volume of the available pocket, 
as well as the presence or absence of stabilizing 
interactions such as charge-charge pairs, 
hydrogen bonding and hydrophobic interactions. 
The S2 pocket in FheproCL1 Gly25 is lined with 
several residues that extend into the active site 
space. These include Leu 67, Met 68, Ala 133, 
Val 157, Ala 160 and Leu 205 (Table 2 and Fig. 
7A). Leu 67 and Val 157 are situated at the 
entrance to the pocket and act as ‘gatekeepers’. 
Met 68, Ala 133 and Ala 160 sit below them, 
deeper into the pocket, while Leu 205 lines the 
floor of the pocket (illustrated in Fig. 7B). 
Sequence alignment and homology based 
modelling of FheCL2 places the following 
residues within the S2 pocket: Tyr 67, Met 68, 
Ala 133, Leu 157, Ala 160 and Leu 205 (Table 
3), all at locations corresponding to those 
observed in the structure of FheCL1 Gly25. The 
differences between the S2 pockets in these 
similar enzymes include the presence of the 










dramatically larger Tyr in the ‘gate-keeping’ 
position 67 at the opening of the S2 pocket, and 
the somewhat larger Leu 157 in the opposing 
position at the entrance to the pocket. While 
tyrosine is much larger and bulkier than leucine, 
it is conformationally able to rotate somewhat 
freely based on the availability of an 
unrestrained torsion angle about the Cα-Cβ bond, 
and its presence at the top of the pocket does not 
necessary preclude the entry of P2 substrate 
residues (Fig. 7).  
In one of the variants of FheCL1 
constructed for this study (FheCL1 Leu67Tyr), a 
substitution of Tyr was made for Leu 67 at the 
opening of the pocket which renders the entrance 
to the S2 pocket somewhat more similar to that 
found in FheCatL2, and human cathepsin K 
(Table 2).  Human cathepsin K is similar to the 
model constructed for FheCL2 sharing the 
presence of a larger Tyr residue at the entrance 
to the pocket. In this structure of human 
cathepsin K (PDB ID 1ATK), the Tyr residue 
does not preclude access to the pocket and is 
positioned such that an inhibitor (E-64) is able to 
bind with a P2 Leu-like moiety just within the 
top of the S2 pocket.  In the second FheCL1 
variant constructed (FheCL1 Leu205Ala), a 
substitution of Ala was made in the Leu 205 
position at the base of the pocket that changed 
this site to be similar to that found in human 
cathepsin L (Table 2). As mentioned above the 
overall structure of the human enzyme is very 




Substrate specificity of FheCL1 and FheCL2 
A comparison of the substrate specificity 
between the F. hepatica cathepsin L peptidases 
(wildtype and variants) and human cathepsin L 
and cathepsin K is shown in Fig. 8, and helps to 
summarise the findings of our substrate 
specificity analyses and the effect active site 
substitutions have on this. Firstly, it is clear that 
both FheCL1 and FheCL2 are similar to 
cathepsin K with regard to their preference for a 
P2 Leu over Phe. Secondly, both enzymes can 
accommodate Pro in the P2 position but this is 
more readily accepted by FheCL2 compared to 
FheCL1; neither enzyme, however, cleaves 
substrates with this residue in the P2 position as 
readily as human cathepsin K.  Thirdly, 
substituting Tyr for Leu at residue 67 (variant 
FheCL1 Leu67Tyr) to make the S2 subsite of 
FheCL1 more like that of human cathepsin K did 
not significantly enhance its ability to cleave 
substrates with Pro in the P2 position; this was 
confirmed using three fluorogenic substrates as 
shown in Table 3, and by PS-SCL as shown in 
Fig. 4. Lastly, Substitution of Leu205 with Ala 
(variant FheCL1 Leu205Ala) increased the 
relative activity of the peptidase for substrates 
with Phe in the P2 position, but this increase was 
not sufficiently dramatic as to reverse its 
preference for Leu over Phe as observed for 
human cathespin L; thus, compared to wildtype 
FheCL1, FheCL1 Leu205Ala is more similar to 
human cathepsin L but is not identical in its 
substrate specificity. 
 Our results using inhibitors are 
consistent with our data derived from the PS-
SCL and substrate specificity studies. FheCL1 
accommodates hydrophobic P2 residues of 
diazomethylketone Z-Phe-Ala-CHN2 more 
effectively than FheCL2 and therefore its 
inhibition by this reagent was two-fold greater. 
Replacement of the Leu205 by Ala, however, 
created an S2 pocket that accepted the P2 Phe 
more readily and hence the inhibitory constant 
for Z-Phe-Ala-CHN2 against the FheCL1 
Leu205Ala variant was 24-fold greater than for 
the wildtype enzyme. The cathepsin K inhibitor 
II, on the other hand, was 20 times more potent 
than Z-Phe-Ala-CHN2 against both FheCL1 and 
FheCL2 and exhibited similar kinetics to that 
reported for human cathepsin K by Wang et al. 
(49). By contrast, it was seven-fold less potent 
against the FheCL1 Leu205Ala variant which is 
interesting since it is 53-fold less effective 
against human cathepsin L, which possesses an 
Ala at position 205, compared to cathepsin K 
(49). Similar to our observations for substrate 
binding the replacement of Leu67 for Tyr did not 
have a dramatic effect on the binding of both 
inhibitors. 
Differences in the substrate specificities 
of human cathepsin L and cathepsin K can be 
exquisitely demonstrated using collagen type 1 
as a substrate. Due to its acceptance of a P2 
proline, cathepsin K can completely degrade 
collagen by cleaving within the repeated Gly-
Pro-Xaa motif in the helices of the tightly-wound 










triple helical structure. Human cathepsin L, on 
the other hand, cleaves within the non-helical 
telomeric regions but does not possess 
intrahelical activity (24, 44). While both FheCL1 
and FheCL2 could cleave native collagen, only 
FheCL2 cleaved this substrate within the helical 
structures. Most strikingly, FheCL2 cleaved 
native collagen even at neutral pH which 
suggests that the enzyme could perform this 
function in vivo to facilitate parasite tissue 
migration. Collectively, these results support the 
idea that FheCL2’s ability to accommodate 
proline in the P2 position of substrates confers 
the enzyme with collagenase-like activity, 
similar to that observed for cathepsin K. 
Although FheCL1 exhibited low activity against 
fluorogenic substrates with a P2 Pro, this was 
insufficient to endow this enzyme the ability to 
cleave the helices within native collagen. 
Replacement of Leu67 in FheCL1 with Tyr 
(FheCL1 Leu67Tyr) to make this enzyme’s S2 
subsite similar to FheCL2 and cathepsin K did 
not enhance it’s ability to accept substrates with 
Pro residues in the P2 position, and nor did it 
confer the enzyme with collagenase-like activity 
suggesting that other S2 residue(s) besides that at 
position 67 is essential for this activity (see 
below). 
 
The amino acid at position 205 lies at the bottom 
of the S2 pocket and has a major impact on 
substrate specificity 
Our PS-SCL, substrate binding and inhibitor 
studies showed that the Leu at position 205 is 
indeed a determinant of substrate turnover and 
inhibitor specificity in FheCL1. The wildtype 
enzyme is able to cleave substrates with Phe in 
the P2 position; however, substrates with the 
much smaller Leu moiety in the P2 position were 
cleaved more than 8-fold more rapidly. In 
comparison to the wildtype FheCL1, replacing 
the Leu with an Ala (FheCL1 Leu205Ala) not 
only enhanced the enzyme’s ability to accept P2 
Phe much more readily, but broadened the 
enzyme’s overall substrate specificity such that 
larger P2 residues such as Tyr and Trp were also 
accepted (see Table 3 and Fig. 4). 
It has been observed in another papain 
family member, cruzain, from the protozoan 
parasite Trypanosoma cruzi, that the character 
(i.e., size, charge and torsion-based flexibility) of 
the residue Glu 205 is crucial for determining 
which P2 residues can be accommodated in the 
S2 pocket (51). Examination of structures of 
cruzain bound to inhibitors containing Phe at P2 
shows that this residue is flexible and can rotate 
in or out of the pocket depending upon the 
substrate residue entering the pocket (51). In 
several inhibitor-bound structures of cruzain 
where the P2 residue is a Phe, Glu 205 is swung 
out into the solvent in order to accommodate the 
size of the phenylalanine (52). In FheCL1, 
however, the Leu at position 205 is shorter by 
one carbon-carbon bond than Glu and, therefore, 
cannot rotate its Cδ1 and Cδ2 out of the pocket. 
While the Leu residue of FheCL1 is shorter than 
cruzain’s Glu by approximately 1.5 Å, it is 
conformationally flexible. It can therefore 
position itself to make the most space possible 
available to an incoming P2 Phe. None-the-less, 
it clearly prefers the smaller Leu. The sidechain 
of the wildtype Leu, as determined in the X-ray 
crystal structure of FheproCL1Gly25, extends 
3.98Å from the bottom of the pocket, filling a 
volume of 166.7 Å3 (53) and exposing a surface 
area of 170 Å2 (54). The observed broader 
specificity of FheCL1 Leu205Ala, i.e. the ability 
to minimally accommodate Tyr and Trp, can 
thus be understood by comparing the space 
available in the base of the S2 pocket. An Ala 
variant at 205 would extend only as far as the Cß 
of Leu, or to a distance of 1.51 Å and a 
corresponding volume of 88.6 Å3 and surface 
area of 115 Å2, leaving considerable additional 
space for larger substrate peptide residues to be 
accommodated.   
 
Ability to cleave proline at P2 is influenced by 
residue 67 and the surrounding ‘gate-keeper’ 
residues. 
By engineering a variant cathepsin K with a Leu 
replacing the Tyr at position 67 Lecaille et al, 
(44) demonstrated an important role for Tyr67 in 
determining the P2 Pro activity of cathepsin K 
and in its unique collagen-cleaving activity. In 
the present study, we found that replacing the 
Leu67 of FheCL1 with a Tyr to engineer the S2 
pocket of the active site of this enzyme to mimic 
FheCL2 and human cathepsin K did not 
significantly alter its S2 subsite specificity, and 
most particularly, did not enhance the enzyme’s 
ability to accept a P2 Pro. The three-dimensional 










structure of FheCL1 was, therefore, analysed and 
compared to cathepsin K to explain these 
observations and determine what additional 
factors within the S2 pocket of FheCL1 may 
influence the acceptance of a P2 Pro residue 
(Fig. 7). 
The S2 pockets of human cathepsin K 
and FheCL2 are very similar, as evidenced by 
our modelling data and that presented in Table 2; 
however, there are some noteworthy differences 
within a 5 Å radius of this site. First, residue 133 
is an alanine in the FheCL2 enzyme but is a 
serine in human cathepsin K. The impact of this 
difference on substrate preference may be 
minimal, however, since this residue is more 
peripheral to the outer edge of the base of the S2 
pocket (Fig. 7). More significant is residue 158, 
which is adjacent to the ‘gate-keeping’ residue 
157, and sits just above the upper lip of the 
pocket. Based on its position, this residue, which 
is Asn in cathepsin K and Thr in FheCL2, 
appears to have some secondary influence on 
accessibility of the opening of the pocket.  In the 
published structure of human cathepsin K (PDB 
ID 1ATK), Asn 158 is swung out of the way of 
the entrance to the pocket and does not preclude 
the entrance of any incoming P2 moiety. 
However, the Thr 158 of FheCL2, which is 
shorter by one carbon than asparagine, cannot 
move completely out of the way and would 
possibly have either a carbon atom or an oxygen 
atom pointing in towards the top of the S2 
opening. Based on spatial constraints, a proline 
would be accommodated in the S2 area of 
FheCL2, but this would as readily accepted as in 
human cathepsin K. Our analysis suggests, 
however, that acceptance of proline in this 
pocket is not achieved by offering a topology of 
easy deep penetration access but rather by 
providing opportunities for stabilizing 
interactions with the 5-membered proline ring of 
the substrate at the entrance to the pocket, and 
that such stabilization involves interactions 
between the aromatic ring of Tyr 67 and the P2 
proline. The location and positioning of Leu 157 
in the structure of human cathepsin K and 
FheCL2 suggests its availability to further 
stabilize the presence of a P2 proline, perhaps 
with constructive aliphatic interactions. 
By comparison, there are greater 
differences in the gate-keeping positions at the 
top entrance to the S2 pocket of FheCL1 
compared to FheCL2 and cathepsin K (Fig. 7). 
Residue 67 is the smaller Leu in FheCL1 and it’s 
terminal carbons, Cδ1 and Cδ2, extend only as far 
as the corresponding Cδ1 and Cδ2 of Tyr which 
stretches its terminal oxygen nearly 3.7 Å further 
from the protein main chain along the edge of 
the pocket. On the opposing side of the pocket 
entrance, residues 158 of FheCL1 is Asn 158, as 
in human cathepsin K, and is swung away from 
the entrance to the pocket, offering unimpeded 
access. However, residue 157 is a Val in 
FheCL1, and is one carbon shorter than the Leu 
found in FheCL2 and human cathepsin K, and 
accordingly its extension into the pocket is 
approximately 1.5 Å less; this does not allow it 
extend far enough into the available space to 
participate in aliphatic interactions.  Thus, the 
absence of both stabilizing Tyr and Leu residues 
would account for the reduced preference for P2 
proline by FheCL1. On the other hand, the 
composition of the S2 pocket in FheCL1, being 
more open and accessible to deeper penetration, 
would more readily favour processing of longer 
amino acid moieties, such as Leu and Phe, as we 
have observed. 
In summary, previous studies with 
human cathepsins K and L have shown that 
residues at positions 67 and 205 are essential in 
dictating substrate specificity (44, 55). Much 
attention, has been given to the importance of a 
Tyr67 in conferring cathepsin K with the ability 
of accepting P2 Pro residues in the 
corresponding S2 subsite of the enzyme and, the 
capacity to degrade native collagens. However, 
this study using FheCL1, and a recent study by 
Lecaille et al, (56) using human cathepsin L 
show that mutations that replace the Leu67 to 
Tyr67 in these enzymes are not sufficient alone 
to accommodate proline and, thus, endow 
collagenolytic activity. Therefore, other residues 
at the opening of the active site pocket, namely 
the gatekeeper residues identified here that 
occupy sites 157 and 158, combine with Tyr to 
generate these specialised properties, and hence, 
we have set the ground for future mutational 
studies. It is important to note that 
glycosaminoglycans such as chondroitin 
sulphate are known to enhance the collagenolytic 
activity of human cathepsin K by binding to a 
site other than the active site (57). However, 










these do not influence the activity of FheCL2 
(data not shown) which points to further 
intriguing differences between the parasite and 
mammalian enzymes. 
Given that collagen is a major interstitial 
matrix protein that is highly resistant to 
proteolysis, our data showing that FheCL2 can 
degrade native collagen within the helical 
regions at physiological pH would suggest that 
this protease enabled Fasciola spp. to become 
proficient tissue-degrading pathogens. It is 
important to note that native collagenase-like 
activity is restricted to very few enzymes. These 
include the bacterial collagenases, matrix-
metalloproteinases and cathepsin K (24) and, 
therefore, the evolution and maintenance of such 
an activity in Fasciola is significant. By 
extension, the emergence of this enzyme group 
may have been essential to the parasites’ 
adaptation to the wide variety of mammalian 
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Sequence alignment of the mature Fasciola hepatica cathepsin L1 (FheCL1) and cathepsin L2 (FheCL2) 
with human cathepsin L (hCatL), human cathepsin K (hCatK) and papain was performed with ClustalW 
(EBI, EMBL). Residues within the S2 subsite of the active site involved in determining substrate 
specificity are indicated with arrows and numbers (see also Table 2). 
 
FIG. 2 
Activation of purified recombinant FheproCL1, and FheproCL2. The 37 kDa zymogens were auto-
catalytically activated and processed to 24.5 kDa mature enzymes by incubation for 2 hours at 37ºC in 0.1 
M sodium citrate buffer pH 5.0, containing 2 mM DTT and 2.5 mM EDTA. Reaction samples were 
analysed by 4-20% SDS-PAGE; lane 1 – 4, activation reaction of FheCL1 at 0, 30, 60 and 120 mins; lane 
5 - 8, activation reaction of FheCL2 at 0, 30, 60 and 120 mins. Similar results were obtained with variant 
peptidases (not shown). MW, molecular mass markers. 
 
FIG. 3  










Profiling of the P1-P4 substrate specificity of FheCL1 and FheCL2 using positional-scanning synthetic 
combinatorial libraries. The y axis represents activity against the substrates relative to the highest activity 
of the library whereas the x axis presents the amino acids as represented by the one-letter code (n = 
norleucine). 
 
FIG. 4  
Comparison of the P2 specificities of recombinant wildtype FheCL1, variant FheCL1 Leu205Ala 
(L205A), variant FheCL1 Leu67Tyr (L67Y) and wildtype FheCL2 using positional-scanning synthetic 
combinatorial libraries. 
 
FIG. 5.  
Comparison of the collagen-cleaving activities of wildtype FheCL1, variant FheCL1 Leu205Ala, variant 
FheCL1 Leu67Tyr and wildtype FheCL2. Panel A, type I collagen was incubated with FheCL1 and 
FheCL2 at pH 4.0 and 5.5 and at 28 ºC for 3 hours and the reaction analysed by 4-20% SDS-PAGE; lane 
1, collagen alone; lane 2 collagen plus FheCL1 pH 4.0; lane 3, collagen plus FheCL2 pH 4.0; lane 4 
collagen alone; lane 5 collagen plus FheCL1, pH 5.5; lane 6, collagen plus FheCL2, pH 5.5. Panel B, type 
I collagen was incubated with active recombinant peptidase (5.47 µM) at 28 ºC at neutral pH (PBS, pH 
7.3) for 20 hours and the reactions analysed as above; lane 1, collagen alone (i.e. no peptidase added); 
lane 2, collagen plus FheCL1; lane 3, collagen plus FheCL1 Leu209Ala; lane 4, collagen plus FheCL1 
Leu67Tyr; lane 5, collagen plus FheCL2. Molecular mass standards are indicated on the right while 
collagen chains (α1, α2, β11, β12 and γ, see 44) are indicated on the right. 
 
FIG. 6  
A, the bi-lobed mature FheproCL1 Gly25 is shown as a cartoon. The predominantly helical domain is at 
right and the predominantly sheet domain is at left. The mutated active site residue Gly25, lies in the cleft 
between the two domains and is indicated in red. B, the structure of full-length FheproCL1 Gly25 zymogen 
is shown, with the mature segment surface illustrated in blue and the prosegment as a cartoon. The 
extended C-terminal portion of the prosegment runs through the active site cleft. The catalytic machinery 
of the enzyme is highlighted in pink.  Figures were created with PyMol (42). 
 
FIG. 7  
A, Surface representation of the active site region of FheproCL1 Gly25. The S2 pocket of the enzyme is 
highlighted in pink and key residues implicated in substrate preference, including the ‘gatekeeper’ 
residues (V157 and N158) are noted. B, Representation of the active site region of FheproCL1 Gly25 and 
FheCL2. The S2 pocket of both enzymes are highlighted. ‘Gatekeeper’ residues of FheproCL1 Gly25 are 
further indicated in pink stick representation and those of the modelled FheCL2 in yellow. Figures created 
with PyMol (42). 
 
FIG. 8  
Comparison of the substrate specificity of human cathepsin L (CL), human cathepsin K (CK), 
recombinant FheCL1, FheCL1 Leu205Ala (L205A), FheCL1 Leu67Tyr (L67Y) and FheCL2.  Data 
shown as relative kcat/KM for the hydrolysis of the substrates Z-Phe-Arg-NHMec, Z-Phe-Leu-NHMec and 
Tos-Gly-Pro-ArgNHMec. *Data for human CL and CK is taken from Lecaille et al. (44). 
 










Table 1. Crystallographic parameters: data collection and refinement statistics 
 
 
Data Collection   
Space Group P21212  
Unit cell parameters   
a (Å) 57.17  
b (Å) 105.78  
c (Å) 49.11  
Wavelength (Å) 1.1159  
Temperature (K) 100  
Resolution (Å) 1.4  
Total number reflections 333582 (19545)  
Total unique reflections 59595 (8465)  
Completeness (%) 99.7 (98.7)  
Redundancy 5.6 (2.3)  
Rmerge 0.080 (0.549)  
Rp.i.m. 0.029 (0.431)  
<I>/<σI> 14.6 (1.8)  
   
Refinement   
Resolution range (Å) 52.93 – 1.40  
Number of reflections 56141  
Rfactor  0.128  
Rfree  0.165  
Free reflections (%) 5.05  
Average B factor (Å2)   
Protein 15.39  
water 34.09  
R.m.s deviation from ideal   
Bond lengths  (Å) 0.020  
Bond angles (º) 1.79  
Ramachandran Plot   
Residues in most favored regions 238 (90.5%)  
Residues in additional allowed regions 25 (9.5%)  
Residues in generously allowed regions 0 (0.0%)  
Residues in disallowed regions 0 (0.0%)  
   
 
Note: Values given in parenthesis in Data Collection section above are for highest resolution bin (1.48-
1.40 Å) 










Table 2. Residues contributing to substrate binding in the S2 subsite of human cathepsin L, human 
cathepsin K, F. hepatica cathepsin L1 (FheCL1), F. hepatica cathepsin L1 Leu67Ala variant (FheCL1 
Leu67Ala), F. hepatica cathepsin L1 Leu205Tyr variant (FheCL1 Leu205Tyr), and F. hepatica cathepsin 
L2 (FheCL2)  
 
                                                 RESIDUE 
      67               68               133             157              158             160              205 
Human cathepsin L Leu Met Ala Met Asp Gly Ala 
Human cathepsin K 
 
Tyr Met Ala Leu Asn Ala Leu 
FheCL1 
 
Leu Met Ala Val Asn Ala Leu 
FheCL1 Leu205Ala 
 
Leu Met Ala Val Asn Ala Ala 
FheCL1 Leu67Tyr 
 
Tyr Met Ala Val Asn Ala Leu 
FheCL2 
 


















Table 3:  Kinetic parameters for hydrolysis of peptidyl-NHMec substrates by recombinant wildtype 






Substrate kcat (s-1) Km (µM) kcat/Km (M-1s-1) 
 
    
FheCL1 Z-FR-NMec 24.69 ± 1.30 24.18 ± 3.92 1,021,092 
FheCL1 Leu205Ala Z-FR-NMec 29.60 ± 1.05 19.21 ± 3.78 1,540,864 
FheCL1 Leu67Tyr Z-FR-NMec 3.58 ± 0.11 8.16 ± 0.86 438,725 
FheCL2 Z-FR-NMec 1.70 ± 0.07 39.94 ± 5.12 42,564 
     
FheCL1 Z-LR-NMec 36.52 ± 0.63 4.35 ± 0.21 8,395,402 
FheCL1 Leu205Ala Z-LR-NMec 9.15 ± 0.24 2.75 ± 0.61 3,327,273 
FheCL1 Leu67Tyr Z-LR-NMec 1.73 ± 0.38 0.38 ± 0.05 4,552,632 
FheCL2 Z-LR-NMec 1.62 ± 0.08 1.39 ± 0.20 1,165,468 
     
FheCL1 Z-PR-NMec 1.03 ± 0.04 191.21 ± 16.90 5,387 
FheCL1 Leu205Ala Z-PR-NMec 0.122 ± 0.005 48.41 ± 4.45 2,479 
FheCL1 Leu67Tyr Z-PR-NMec 0.62 ± 0.04 136.98 ± 12.03 4,526 
FheCL2 Z-PR-NMec 2.64 ± 0.13 84.03 ± 11.28 31,417 
     
FheCL1 Tos-GPR-NMec 0.36 ± 0.03 10.02 ± 1.20 35,928 
FheCL1 Leu205Ala Tos-GPR-NMec 0.113 ± 0.003 20.35 ± 1.00 5,405 
FheCL1 Leu67Tyr Tos-GPR-NMec 0.26 ± 0.01 6.96 ± 1.08 37,069 
FheCL2 Tos-GPR-NMec 1.17 ± 0.08 15.33 ± 2.62 76,321 
     
FheCL1 Boc-AGPR-NMec 0.48 ± 0.03 10.43 ± 2.63 46,021 
FheCL1 Leu205Ala Boc-AGPR-NMec 0.20 ± 0.04 21.57 ± 8.85 9,179 
FheCL1 Leu67Tyr Boc-AGPR-NMec 0.93 ± 0.03 11.13 ± 1.37 83,378 
FheCL2 Boc-AGPR-NMec 2.48 ± 0.08 33.69 ± 0.99 73,731 
     
 










Table 4:  Inactivation of recombinant wildtype FheCL1, variants FheCL1 Leu205Ala, FheCL1 Leu67Tyr 





kobs/[I] (M-1s-1) Ki(app) (nM) 
FheCL1 20,838 ± 589 1,125 ± 213 
FheCL1 Leu209Ala 492,727 ± 12592 15.4 ± 3.44 
FheCL1 Leu67Tyr 53,704 ± 4331 93.6 ± 9.1 
FheCL2 11,899 ± 477 1,670.7 ± 791 















Table 5:  Inhibition values for recombinant wildtype FheCL1, variants FheCL1 Leu205Ala, FheCL1  





kobs/[I] (M-1s-1) Ki(app) (nM) 
FheCL1  397,237 ± 55370 10.80 ± 0.48 
FheCL1 Leu209Ala 58,212 ± 5306 116.33 ± 24.40 
FheCL1 Leu67Tyr 113,182 ± 8220 13.27 ± 0.87 
FheCL2 269,447 ± 4611 23.14 ± 3.59 
   
cathepsin K a 590,000 ± 1200 6.0 
cathepsin L a 11,000 ± 560 - 
 
a
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